Alliance Pharma expects to post flat annual profit, revenue decline

(Alliance News) - Alliance Pharma PLC on Friday said it expects to report 2024 profit broadly in ...

Alliance News 31 January, 2025 | 11:58AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Alliance Pharma PLC on Friday said it expects to report 2024 profit broadly in line with the year before, despite a decline in annual revenue.

The Chippenham, Wiltshire-based distributor of consumer healthcare brands and prescription medicines said it expects to report revenue of GBP180.3 million for 2024, down 1.3% from GBP182.7 million a year prior.

Revenue within its Kelo-Cote franchise grew 3.4% at constant exchange rates to GBP65.4 million from GBP63.2 million, in line with its mid-single digit revenue growth forecast.

The group is targeting a transition to smaller, more regular orders in China, though it notes that this is taking "longer than we anticipated".

Nizoral revenue sank 28% during the year to GBP16.4 million from GBP21.7 million, due to the timing of distributor orders, while Amberen revenue fell 10% to GBP10.1 million from GBP11.2 million.

Total see-through Consumer Healthcare revenue declined 4.3% at CER to GBP130.7 million from GBP136.4 million.

On the other hand, Prescription revenue grew 6.9% to GBP49.6 million, Forceval revenue rose 18% to GBP7.9 million, and Hydromol revenue was up 13% on-year to GBP10.3 million.

Alliance Pharma still anticipates underlying group profit for the year in line with the GBP31.5 million reported for 2023.

Chief Executive Officer Nick Sedgwick said: "I am pleased that performance in 2024 is in-line with expectations. Whilst we have much to do as we work on our transformation plans, I am confident that our strong portfolio of clinically differentiated brands will deliver predictable organic revenue growth over the mid-long term."

Shares in Alliance Pharma were flat at 61.20 pence each in London on late Friday morning.

By Emily Parsons, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Alliance Pharma PLC 61.30 GBX 0.16 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures